Form 4: Amylyx Pharmaceuticals Co-CEO Sells Shares to Cover Tax Obligations

Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On March 31, 2025, Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, sold 21,490 shares of common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $3.4659, with individual transactions ranging from $3.435 to $3.58.
• Following the transaction, Cohen directly owns 3,355,280 shares of Amylyx Pharmaceuticals.
• The sale was automatic and not at the discretion of the reporting person.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

Sales of shares by company executives are a normal part of executive compensation and wealth management. It is important to consider the context of the sale, such as the reason for the sale and the amount of stock the executive still holds.

Stakeholder Impact

• The sale of shares by a company executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the reason for the sale.

Key Dates

Keywords

Amylyx Pharmaceuticals, Joshua B. Cohen, stock sale, Form 4, tax withholding, restricted stock units, AMLX